Obesity and venous thrombotic disease;Adipositas und thrombotische gefasserkrankungen

Zentralblatt fur Gynakologie

Volumn 120, Issue 5, 1998, Pages 246-250

  Winkler, U H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Arterial thrombosis metabolic syndrome; Obesity; Venous thrombosis

Indexed keywords

ARTICLE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MENOPAUSE; METABOLIC DISORDER; OBESITY; PREGNANCY COMPLICATION; VEIN THROMBOSIS; ANTHROPOMETRY; BODY MASS; FEMALE; PREGNANCY; REVIEW; RISK FACTOR; THROMBOPHLEBITIS;

ANTHROPOMETRY; BODY MASS INDEX; FEMALE; HUMANS; OBESITY; PREGNANCY; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0031775813     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line hep G2. Thromb Haemostas 60 (1988) 491-494
2. Back DJ, Power J, Winkler UH, Schindler AE, Daume E, Simon A, Neiss A, Hammerstein J: Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. Adv Contracep 9 (1993) 319-330
3. Bara L, Nicaud V: Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIc and PAI-1 in European offspring-th EARS study. Thromb Haemostas 71 (1994) 434-440
4. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP: Resistance to activated protein C and factor V leiden as risk factors for venous thrombosis. Thromb Haemostas 74 (1995) 449-453
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
6. Cohen JC, Hickman R: Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 64 (1987) 960-963
7. Dahlbäck B: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 85 (1995) 607-612
8. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996) 977-980
9. Farmer RDT, Lewis M, Lunsen HW van, Cohen J: Oral contraceptives and mortality from venous thromboembolism. Lancet 348 (1996) 1095-1096
10. Ferraro R, Lillioja S, Fontvieille AM, Rising R, Bogardus C, Ravussion E: Lower sedentary metabolic rate in women compared with men. J Clin Invest 90 (1992) 780-784
11. Gorodeski GI, Utian WH: Epidemiology and risk factors of cardiovascular disease in postmenopausal women. In: Treatment of postmenopausal woman: Basic and clinical aspects. Ed.: Lobo RA., 1994, 199-221
12. Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F: Shortterm infusions of insulin, triacylglycerol and glucose do not cause acute increases inplasminogen activator inhibitor-1 concentrations in man. Clin Sci 79 (1990) 513-516
13. Griffiths M, Payne PR, Stunkard AJ, Rivers JPW, Cox M: Metabolic rate and physical development in children at risk of obesity. Lancet 336 (1990) 76-78
14. Hamsten A, Wiman B, De Faire U, Blombäck M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313 (1985) 1558-1563
15. Hamsten A, Walldius G, Szamosi A, Blombäck M, De Faire U, Dahlen G, Landou C, Wimann B: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet July (1987) 3-9
16. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
17. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
18. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemostas 61 (1989) 370-373
19. Kaplan NM: The deadly quartet. Arch Intern Med 149 (1989) 1514-1520
20. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocr Metab 54 (1982) 254-260
21. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM: APC-resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 84 (1994) 1031-1035
22. Manson JE, Colditz GA, Stampfer MJ et al: A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 332 (1990) 882-889
23. Nicoloso G, Hauert J, Kruithof EKO, van Melle G, Bachmann F: Fibrinolysis in normal subjects - comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemostas 59 (1988) 299-303
24. Peins AN, Mueller RA, Struve MF, Smith GA, Kissebah AH: Relationship of androgenic activity to splanchnik insulin metabolism and peripheral glucose utilization in premenopausal women. J Clin Endocrinol Metab 64 (1987) 162-169
25. Primrose JN, Davies JA: Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemostas 68 (1992) 396-399
26. Roberts SB, Savage J, Coward WA, Chew B, Lucas A: Energy expenditure and energy intake in infants born to Lean and overweight mothers. N Engl J Med 318 (1988) 461-466
27. Ruderman NB, Schneider SH, Berchtold P: The "metabolically-obese," normal-weight individual. Am J Clin Nutr 34 (1981) 1617-1621
28. Seligsohn U, Zivelin A: Thrombophilia as a multigenic disorder. Thromb Haemostas 78 (1997) 297-301
29. Siegert G, Bergmann S, Jaross W, Assmann G: Abhängigkeit der Hämostaseparameter Fibrinogen, Plasminogenaktivatorinhibitor und Antithrombin III von Alter und Geschlecht sowie ihre Beziehung zu bekannten Risikofaktoren der Atherosklerose in der Bevölkerung von Dresden und Umgebung (DRECAN-Studie). Klinisches Labor 38 (1992) 499-505
30. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 312 (1996) 83-88
31. Thromboembolic Risk Factors (THRIFT) Consensus Group: Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 305 (1992) 567-74
32. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C: Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38 (1989) 913-915
33. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35 (1986) 250-253
34. van der Meer FJM, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR: The Leiden thrombophilia study (LETS). Thromb Haemostas 78 (1997) 631-635
35. Van Itallie TB: Health implications of overweight and obesity in the United States. Ann Intern Med 103 (1985) 983-988
36. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: results of international multicentre case-control study. Lancet 346 (1995) 1575-1582
37. Wiman B: Plasminogen Activator Inhibitor-1 (Pai-1) in plasma: Its role in thrombotic disease. Thromb Haemostas 74 (1995) 340-346